BR112023025403A2 - Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo - Google Patents
Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmoInfo
- Publication number
- BR112023025403A2 BR112023025403A2 BR112023025403A BR112023025403A BR112023025403A2 BR 112023025403 A2 BR112023025403 A2 BR 112023025403A2 BR 112023025403 A BR112023025403 A BR 112023025403A BR 112023025403 A BR112023025403 A BR 112023025403A BR 112023025403 A2 BR112023025403 A2 BR 112023025403A2
- Authority
- BR
- Brazil
- Prior art keywords
- heterocyclic compound
- ubiquitin
- same
- pathway
- function
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 4
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 230000015556 catabolic process Effects 0.000 title abstract 3
- 238000006731 degradation reaction Methods 0.000 title abstract 3
- 102000044159 Ubiquitin Human genes 0.000 title 1
- 108090000848 Ubiquitin Proteins 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo. a presente invenção refere-se a um composto heterocíclico e a uma composição para prevenir ou tratar um câncer, uma doença autoimune e uma doença inflamatória, compreendendo o mesmo. o novo composto heterocíclico da presente invenção é um composto bifuncional com função de degradação da tirosina quinase de bruton (btk) através de uma via do proteassoma da ubiquitina e pode ser usado como uma composição para prevenir ou tratar um câncer, uma doença autoimune e doença de parkinson.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210083326 | 2021-06-25 | ||
| KR1020220077174A KR102637915B1 (ko) | 2021-06-25 | 2022-06-23 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
| PCT/KR2022/009087 WO2022270994A1 (ko) | 2021-06-25 | 2022-06-24 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025403A2 true BR112023025403A2 (pt) | 2024-02-20 |
Family
ID=84544657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025403A BR112023025403A2 (pt) | 2021-06-25 | 2022-06-24 | Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU2022297176A1 (pt) |
| BR (1) | BR112023025403A2 (pt) |
| CA (1) | CA3223447A1 (pt) |
| WO (1) | WO2022270994A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023242597A1 (en) * | 2022-06-16 | 2023-12-21 | Amphista Therapeutics Limited | Bifunctional molecules for targeted protein degradation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008147831A1 (en) | 2007-05-23 | 2008-12-04 | Smithkline Beecham Corporation | Anthranilamides |
| TN2016000094A1 (en) | 2013-09-30 | 2017-07-05 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase. |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| PL3660004T3 (pl) | 2016-10-11 | 2023-10-02 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
| US10994015B2 (en) | 2016-12-23 | 2021-05-04 | Arvinas Operations, Inc. | EGFR proteolysis targeting chimeric molecules and associated methods of use |
| WO2018140809A1 (en) | 2017-01-26 | 2018-08-02 | Arvinas, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| WO2018208132A1 (en) * | 2017-05-12 | 2018-11-15 | Korea Research Institute Of Chemical Technology | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient |
| KR102128018B1 (ko) | 2017-05-12 | 2020-06-30 | 한국화학연구원 | 피라졸로 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암, 자가면역질환 및 뇌질환의 예방 또는 치료용 약학적 조성물 |
| CN109422752B (zh) * | 2017-09-03 | 2023-04-07 | 上海美志医药科技有限公司 | 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物 |
| WO2019136016A1 (en) | 2018-01-02 | 2019-07-11 | Celgene Corporation | Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| TW201945357A (zh) | 2018-02-05 | 2019-12-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| WO2019186358A1 (en) | 2018-03-26 | 2019-10-03 | Novartis Ag | 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives |
| CN108959540A (zh) | 2018-06-30 | 2018-12-07 | 广东技术师范学院 | 一种用于隐性关联知识发现的多关系融合方法及智能化*** |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3841098A4 (en) | 2018-08-22 | 2022-05-04 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHOD OF USE |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| KR102642203B1 (ko) | 2018-09-07 | 2024-03-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| WO2020160193A2 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN113874016A (zh) | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| EP3922632A4 (en) | 2019-02-07 | 2023-02-15 | Korea Research Institute of Chemical Technology | DEGRADATION AGENT THAT INDUCES DEGRADATION OF A TARGET EED PROTEIN, METHOD FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EED, EZH2 OR PRC2 USING SUCH AGENT AS THE ACTIVE SUBSTANCE |
| US20220143195A1 (en) | 2019-02-13 | 2022-05-12 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| WO2020200291A1 (en) | 2019-04-02 | 2020-10-08 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
| US20220372017A1 (en) | 2019-06-24 | 2022-11-24 | Dana-Farber Cancer Institute, Inc. | Hck degraders and uses thereof |
| WO2021058017A1 (en) | 2019-09-29 | 2021-04-01 | Beigene, Ltd. | Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use |
| CN110724143B (zh) * | 2019-10-09 | 2021-03-23 | 清华大学 | 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫***疾病与肿瘤中的应用 |
-
2022
- 2022-06-24 CA CA3223447A patent/CA3223447A1/en active Pending
- 2022-06-24 WO PCT/KR2022/009087 patent/WO2022270994A1/ko active Application Filing
- 2022-06-24 AU AU2022297176A patent/AU2022297176A1/en active Pending
- 2022-06-24 BR BR112023025403A patent/BR112023025403A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022297176A1 (en) | 2024-01-04 |
| WO2022270994A1 (ko) | 2022-12-29 |
| CA3223447A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| DOP2019000163A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| BR112022002991A2 (pt) | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| SV2008002963A (es) | Triazolopiridazinas como moduladores de tirosina cinasa referencia cruzada con solicitudes relacionadas ref. prd2584sv | |
| BR0317110A (pt) | Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos | |
| BR112012004453A8 (pt) | composto inibidor de proteína quinase, sua composição farmacêutica e seu uso | |
| ECSP22083904A (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| BRPI0507744A (pt) | caracterìsticas de vestimenta absorvente para eliminação de arqueamento | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| BR112023025403A2 (pt) | Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo | |
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| BR112022002532A2 (pt) | Compostos heterocíclicos como inibidores de quinase | |
| ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
| CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
| ES2063073T3 (es) | Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios. | |
| DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| BRPI0911681B8 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro | |
| GT200600254A (es) | Moduladores de aminoquinolina y aminoquinazolina quinasa | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| CL2020001349A1 (es) | Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574) | |
| CL2012001072A1 (es) | Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas. | |
| DOP2022000232A (es) | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 | |
| BR112023021265A2 (pt) | Moduladores da proteólise de bcl6 e métodos de uso associados | |
| BR112016006444A2 (pt) | derivado de triazolopirazina e uso do mesmo |